Vanguard Portfolio Management
AKBA icon

Vanguard Portfolio Management’s Akebia Therapeutics AKBA Stock Holding History

Vanguard Portfolio Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.89M Buy
2,533,977
+318,536
+14% +$379K ﹤0.01% 2617
2026
Q1 		$3.08M Buy
+2,215,441
New +$3.04M ﹤0.01% 2467

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return

Vanguard Portfolio Management's AKBA Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Akebia Therapeutics (AKBA) stake by 14% in Q2 2026, buying an estimated $379K and bringing the position to 2,533,977 shares worth $2.89M. The position accounts for ﹤0.01% of the portfolio, ranked #2617.

Vanguard Portfolio Management first reported a position in AKBA in Q1 2026 and has held it in 2 quarters since. The position peaked at $3.08M in Q1 2026. 155 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Vanguard Portfolio Management held 2,533,977 shares of Akebia Therapeutics worth $2.89M as of Q2 2026.
  • Vanguard Portfolio Management bought 318,536 Akebia Therapeutics shares in Q2 2026, an estimated $379K.
  • Akebia Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2617 holding.
  • Vanguard Portfolio Management first reported a position in Akebia Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Portfolio Management's Akebia Therapeutics position peaked at $3.08M in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.